Sanofi SA (SASY.PA)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2015||Independent Chairman of the Board|
|61||2015||Chairman of the Executive Committee, Chief Executive Officer, Director|
|59||2009||Executive Vice President, Chief Financial Officer, Member of the Executive Committee|
|58||2014||Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee|
|54||2016||Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee|
- Fed Circuit blocks generic versions of Sanofi atrial fibrillation drug
- Sanofi strikes licence deal with Principia Biopharma on multiple sclerosis
- Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales
- UPDATE 3-Regeneron Q3 profit easily tops Street view on Eylea, Dupixent sales
- BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln